Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 457
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) inhibitor, R935788 (R788), at a dose of 100 mg, orally, twice-a-day, and/or a dose of of 150 mg, orally, once-a-day is effective in the treatment of Rheumatoid Arthrits in patients who have had an inadequate clinical response to methotrexate.

Detailed description:

Arms:
arm 1: R788, 100 mg tablet, orally, twice-a-day arm 2: R788, 150 mg tablet, orally, once a day arm 3: Placebo, orally, either once a day, or twice a day

Interventions: intervention 1: Fostamatinib disodium (R935788) intervention 2: Fostamatinib disodium (R935788) intervention 3: Placebo
Intervention descriptions: intervention 1: 100 mg tablet, orally, twice-a-day intervention 2: 150 mg tablet, orally, once a day intervention 3: Placebo, orally, either once a day, or twice a day

Protocol document: